Literature DB >> 19679601

Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors.

H von Baum1, T Welte, R Marre, N Suttorp, S Ewig.   

Abstract

The aim of the present study was to determine the relevance of the presence of Enterobacteriaceae (EB) and Pseudomonas aeruginosa (PA) in patients with community-acquired pneumonia (CAP) and how the true incidence of these pathogens can be assessed. Based on prospective data from 5,130 patients with CAP included in the German Competence Network for Community-Acquired Pneumonia (CAPNETZ), the incidence, clinical characteristics, outcome and predictors of patients with CAP due to EB and PA were studied applying strict case definitions. The incidence of EB was 67 (1.3%) out of 5,130, including 27 patients with bacteraemia. PA was found in 22 (0.4%) out of 5,130 patients. These microorganisms were judged to be indeterminate pathogens in an additional 172 and 27 isolates, respectively. Patients with indeterminate pathogens differed considerably from those with definite isolates in terms of clinical presentation, comorbidity, pneumonia severity and outcome. Independent risk factors for EB included cardiac and cerebrovascular disease, and for PA chronic respiratory disease and enteral tube feeding. The 30-day mortality was significantly higher in patients with definite pathogens. In the present large population, the incidence of CAP due to EB/ PA was low. The risk of the presence of these pathogens can be assessed using several predictors, which may identify those patients in need of an extended diagnostic work-up and initial antimicrobial treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19679601     DOI: 10.1183/09031936.00091809

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  39 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  [Severe pneumonia in the intensive care unit].

Authors:  T Welte
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-05-09       Impact factor: 0.840

3.  Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.

Authors:  Elena Laserna; Oriol Sibila; Juan Felipe Fernandez; Diego Jose Maselli; Eric M Mortensen; Antonio Anzueto; Grant Waterer; Marcos I Restrepo
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

4.  [Community-acquired pneumonia].

Authors:  K Dalhoff
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

5.  [Community-acquired pneumonia: a disease of the elderly].

Authors:  T Welte
Journal:  Z Gerontol Geriatr       Date:  2011-08       Impact factor: 1.281

6.  Impact of bacterial coinfection on clinical outcomes in pneumococcal pneumonia.

Authors:  S Kumagai; T Ishida; H Tachibana; Y Ito; A Ito; T Hashimoto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-10       Impact factor: 3.267

Review 7.  Will polymerase chain reaction (PCR)-based diagnostics improve outcome in septic patients? A clinical view.

Authors:  Mathias W Pletz; Nele Wellinghausen; Tobias Welte
Journal:  Intensive Care Med       Date:  2011-05-15       Impact factor: 17.440

8.  Community-Acquired Pneumonia in Adults.

Authors:  Martin Kolditz; Santiago Ewig
Journal:  Dtsch Arztebl Int       Date:  2017-12-08       Impact factor: 5.594

9.  The Nonantibiotic Macrolide EM703 Improves Survival in a Model of Quinolone-Treated Pseudomonas aeruginosa Airway Infection.

Authors:  Gopinath Kasetty; Ravi K V Bhongir; Praveen Papareddy; Heiko Herwald; Arne Egesten
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

10.  Thin-section CT findings in Pseudomonas aeruginosa pulmonary infection.

Authors:  F Okada; A Ono; Y Ando; T Nakayama; R Ishii; H Sato; A Kira; I Tokimatsu; J Kadota; H Mori
Journal:  Br J Radiol       Date:  2012-07-27       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.